IMMP - Immutep in pact with Northway Biotech to manufacture IMP761

Immutep (NASDAQ:IMMP) has signed a Manufacturing Service Agreement (MSA) with Northway Biotech to manufacture IMP761 ahead of clinical testing. Under the agreement, Northway has already started developing a GMP-compliant manufacturing process of IMP761 and will manufacture the drug in large scale bioreactors. The work is undertaken at Northway’s Vilnius, Lithuania facility with the potential to expand the agreement to include further process scale up and cover commercial supply in the future. After completion of the required preclinical development, the material produced will be used for Immutep’s clinical trials of IMP761. Planning for further pre-clinical and clinical development is ongoing. IMP761, a preclinical candidate for autoimmune diseases is an immunosuppressive agonist antibody to LAG-3. It has been tested in a Th1-driven autoimmune disease setting, oligoarticular juvenile idiopathic arthritis. Recently, IMMP reported good patient safety in efti triple combination study.

For further details see:

Immutep in pact with Northway Biotech to manufacture IMP761